Biogen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of neurological disease research since its founding in 1978. With a strong presence in North America, Europe, and Asia, Biogen focuses on developing innovative therapies for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. Renowned for its pioneering work in monoclonal antibodies, Biogen's core products include the multiple sclerosis treatments Tecfidera and Ocrevus, which are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including the first FDA approval of a treatment for spinal muscular atrophy in 2016. As a key player in the biotechnology industry, Biogen continues to push the boundaries of science, solidifying its market position through a commitment to research and development, and a robust pipeline of potential therapies.
How does Biogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Biogen's score of 91 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Biogen reported total carbon emissions of approximately 324,178,000 kg CO2e, with Scope 1 emissions at about 56,611,000 kg CO2e, Scope 2 emissions at approximately 507,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled about 267,059,000 kg CO2e. This represents a decrease from 2023, where total emissions were approximately 361,715,000 kg CO2e. Biogen has set ambitious climate commitments, aiming for a 55% reduction in absolute Scope 1 and 2 emissions by 2032 from a 2019 baseline. Furthermore, the company has pledged to achieve net-zero emissions across its entire value chain by 2045. This includes a long-term goal of eliminating Scope 1 and 2 emissions entirely by 2040 and reducing Scope 3 emissions by 90% by 2045. The company is also focused on its supply chain, with a target that 80% of its suppliers, by spend, will have science-based targets by 2025. These commitments align with industry standards and reflect Biogen's dedication to addressing climate change and reducing its carbon footprint.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 60,179,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 187,000 | 000,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
Scope 3 | 262,358,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.